Without a discussion of the power of this study to detect nominally significant differences in the secondary endpoints (“nominally” because they were apparently not alpha protected), a lack of “significant” differences in MACE, malignancies or other events could simply reflect lack of power.
For example, a “true” malignancy HR of 1.32 might not be dismissed.